课题基金 / 基金详情

Identification of plasma lipoprotein proteins and lipids as biomarkers of innate-immunity and vascular contributions to Alzheimer's disease and Alzheimer's disease-related dementias in older adults

Identification of plasma lipoprotein proteins and lipids as biomarkers of innate-immunity and vascular contributions to Alzheimer's disease and Alzheimer's disease-related dementias in older adults
鉴定血浆脂蛋白和脂质作为老年人阿尔茨海默病和阿尔茨海默病相关痴呆的先天免疫和血管贡献的生物标志物
批准号:
10660037
负责人:
Danni Li
金额:
$223.25万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2023
资助国家:
美国
项目状态:
未结题
起止时间:
2023-06-01 至 2026-05-31

项目摘要

项目成果

Danni Li的其他基金

相似基金

相关文献

中文摘要
翻译
项目总结。目前迫切需要充分了解阿尔茨海默病(AD)的复杂性。
英文摘要
Project Summary. Critical needs exist to fully understand the complexity of Alzheimer’s disease (AD) pathophysiology and more accurately characterize AD using biomarkers beyond amyloid, tau, and neuronal injury (AT[N]). Vascular pathology substantially increases the risk of AD and AD-related dementias (ADRDs) and coexists with AD pathology (brain amyloid deposition) in the majority of AD/ADRD cases. Neuroinflammation underlies the development of both vascular and AD pathologies and is modulated by peripheral factors that exacerbate or attenuate cognitive decline. Evidence suggests that plasma lipoproteins influence the development of brain amyloid deposition and cerebral small vessel diseases and underlying neuroinflammation, neurodegeneration, and AD/ADRD sequelae (cognitive decline and incident dementia). The objective of this proposal is to identify protein and lipid cargo of plasma lipoproteins that are associated with AD pathology, vascular pathology, neuroinflammation, neurodegeneration, cognitive decline, and incident dementia in older adults. The central hypotheses are that plasma lipoproteins influence brain amyloid deposition, vascular pathology, and neuroinflammation, and alter neurodegeneration and trajectories of cognitive decline and incident dementia. This proposed study will employ already-collected plasma samples and outcome data from the Atherosclerosis Risk in Communities Neurocognitive Study (ARIC-NCS). We identified 743 eligible ARIC-NCS participants without dementia (mean age: 76.4 years) who had blood collected at baseline and had baseline plasma measures of brain amyloid deposition (Ab 42/40 ratio, p-tau 181), neuroinflammation (GFAP), and neurodegeneration (NfL) available. These participants also had central arterial stiffness and cognitive function and status evaluated at baseline, concurrent with the baseline blood collection that we will use for our plasma lipoprotein fractionation, and had cognitive function and status evaluated twice more over a mean follow-up period of 6.5 years. We will randomly select 346 participants and fractionate their plasma samples, measure proteins and lipids in 1384 fractionated plasma lipoproteins (346 of each fraction [VLDL, IDL, LDL, HDL]) using MS-based proteomics and lipidomics, respectively, and identify proteins, lipids, or their interactions in plasma lipoproteins in relation to AD/ADRD-related outcomes. The specific aims are: 1) Determine proteins or lipids in fractionated plasma lipoproteins as biomarkers indicative of AD pathology and vascular pathology; 2) Establish proteins or lipids in fractionated plasma lipoproteins as biomarkers suggestive of neuroinflammation and neurodegeneration; and 3) Identify proteins or lipids in fractionated plasma lipoproteins as biomarkers predictive of cognitive decline and incident dementia. Our proposal will broaden our perspective and understanding of peripheral factors in the development of AD/ADRD pathophysiology and will identify potentially useful plasma lipoprotein–based therapeutic strategies and biomarkers beyond the current AT[N] paradigm for treating or preventing AD/ADRDs.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Blood Biomarkers as Surrogate Endpoints of Treatment Responses to Aerobic Exercise and/or Cognitive Training in Amnestic Mild Cognitive Impairment
  • 批准号:
    10190758
  • 项目类别:
  • 资助金额:
    $48.02万
  • 财政年份:
    2018
  • 负责人:
    Danni Li
  • 依托单位:
Blood Biomarkers as Surrogate Endpoints of Treatment Responses to Aerobic Exercise and/or Cognitive Training in Amnestic Mild Cognitive Impairment
  • 批准号:
    10572816
  • 项目类别:
  • 资助金额:
    $23.57万
  • 财政年份:
    2018
  • 负责人:
    Danni Li
  • 依托单位:
Blood Biomarkers as Surrogate Endpoints of Treatment Responses to Aerobic Exercise and/or Cognitive Training in Amnestic Mild Cognitive Impairment
  • 批准号:
    9752399
  • 项目类别:
  • 资助金额:
    $49.61万
  • 财政年份:
    2018
  • 负责人:
    Danni Li
  • 依托单位:
国内基金
海外基金
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
  • 批准号:
    JCZRQN202500010
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
  • 依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
  • 批准号:
    2025JJ70209
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
    雷芬芳
  • 依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
  • 批准号:
    --
  • 项目类别:
    面上项目
  • 资助金额:
    --
  • 批准年份:
    2024
  • 负责人:
    万荣
  • 依托单位: